

Our Ref: 318
May 2024

Re: Your request made under the Freedom of Information Act 2000

We are analysing the usage of biologic and biosimilar products within Rheumatology and it would be really helpful if you could please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia] - 16
- Adalimumab [Humira] - 27
- Adalimumab Biosimilars - 414
- Apremilast [Otezla] - 2
- Baricitinib [Olumiant] - 47
- Bimekizumab [Bimzelx] - 0
- Certolizumab [Cimzia] - 17
- Etanercept [Enbrel] - 25
- Etanercept Biosimilars - 175
- Filgotinib [Jyseleca] - 59
- Golimumab [Simponi] - 38
- Guselkumab [Tremfya] - 3
- Infliximab [Remicade] - 6
- Infliximab Biosimilars - 15
- Ixekizumab [Taltz] - 7
- Risankizumab [Skyrizi] - 0
- Rituximab [MabThera] - 0
- Rituximab Biosimilars - 19
- Sarilumab [Kevzara] - 4
- Secukinumab [Cosentyx] - 53
- Tocilizumab [Ro Actemra] - 13
- Tocilizumab Biosimilars - 0
- Tofacitinib [Xeljanz] - 3
- Upadacitinib [Rinvoq] - 23
- Ustekinumab [Stelara] - 3